Allergy

GSK's Flonase tops allergy category

The new OTC medication almost hit $100 million in sales in its first 16 weeks on the market.

WebMD: Pollen Vortex is here

The medical website says the country is in for a bad allergy season.

Tuesday: FDA panel reviews Merck's Ragwiteck

Preliminary documents suggest a positive view for the under-the-tongue medication.

Shutdown delays some FDA committees

User fees keep the regulator's review process running for some drugs, while others see review dates slip.

Mylan expands Get Schooled anaphylaxis tool box

Mylan expands Get Schooled anaphylaxis tool box

By

The EpiPen manufacturer's latest effort: an e-book that shows children making allergy-friendly swaps at a school event.

Business briefs: Sanofi, Celgene, plus changing cancer definitions

Sanofi may make OTC history; Celgene joins a new collaboration; and the US Task Force of Preventative Medicine wants to make lung cancer screening the norm

Finding opportunity in FDA focus on drugged driving

Finding opportunity in FDA focus on drugged driving

By

With its recent actions on sleep aids and allergy medications, the FDA is demonstrating growing concern about the effects of prescription drugs on driving. One CRO is fielding a fleet of driving simulators to help manufacturers salve the agency's worries.

Ex-NFLer, Sanofi talk anaphylaxis

Ex-NFLer, Sanofi talk anaphylaxis

By

The company's latest outreach, an Auvi-Q promotion, breaks down allergy management into sports playbook presentation.

Mylan expands Epi-Pen strategy

Mylan expands Epi-Pen strategy

By

Emmy-winner Julie Bowen is part of the effort to spread allergy education and awareness in schools.

Sanofi's talking allergy device an answer to Dey's EpiPen

Sanofi's talking allergy device an answer to Dey's EpiPen

By

The drugmaker's new auto-injecting epinephrine pen provides verbal cues during emergency allergic situations. It's the latest entry in a competitive market.

Dey launches EpiPen app

Dey launches EpiPen app

By

Mylan's Dey Pharma launched MyEpiPen App, designed to help patients with severe allergies and their caregivers cope with episodes of anaphylaxis.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.